A Three-Way Accuracy Comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense Continuous Glucose Monitoring Devices in a Home-Use Study of Subjects with Type 1 Diabetes

There is a dearth of comparative accuracy studies of continuous glucose monitoring (CGM) devices in the home-use setting, and none with the Eversense implantable CGM. We evaluated the accuracy of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense during a 6-week free-living home-use...

Full description

Saved in:
Bibliographic Details
Published inDiabetes technology & therapeutics Vol. 22; no. 11; p. 846
Main Authors Jafri, Rabab Z, Balliro, Courtney A, El-Khatib, Firas, Maheno, Michele M, Hillard, Mallory A, O'Donovan, Alexander, Selagamsetty, Rajendranath, Zheng, Hui, Damiano, Edward R, Russell, Steven J
Format Journal Article
LanguageEnglish
Published United States 01.11.2020
Subjects
Online AccessGet more information

Cover

Loading…
Abstract There is a dearth of comparative accuracy studies of continuous glucose monitoring (CGM) devices in the home-use setting, and none with the Eversense implantable CGM. We evaluated the accuracy of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense during a 6-week free-living home-use bionic pancreas study involving 23 subjects with type 1 diabetes who wore all three devices concurrently. The primary outcome was the mean absolute relative difference (MARD) between CGM readings and point-of-care (POC) plasma-glucose (PG) values obtained approximately twice daily by the subjects. We compared PG values with CGM readings when available from all three CGMs in the 5 min preceding the PG values (  = 829 sets). Since the Libre Pro records readings every 15 min, we also did a two-way comparison between the G5 and the Eversense with a higher number of comparisons (  = 2277 sets). All three CGM systems produced higher average MARDs than during in-clinic studies. However, since all three CGM systems were worn by the same individuals and used the same meter for comparator PG measurements, we could directly compare their performances. In the three-way comparison, Eversense achieved the lowest nominal MARD (14.8%) followed by Dexcom G5 (16.3%) and Libre Pro (18.0%) (Eversense vs. Libre Pro  = 0.004, other comparisons  = NS). There was a statistically significant difference (  = 0.008) in the two-way comparison of the MARDs for Eversense (15.1%) and G5 (16.9%). The point accuracy of the Eversense was better than two other CGMs when compared with POC PG values.
AbstractList There is a dearth of comparative accuracy studies of continuous glucose monitoring (CGM) devices in the home-use setting, and none with the Eversense implantable CGM. We evaluated the accuracy of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense during a 6-week free-living home-use bionic pancreas study involving 23 subjects with type 1 diabetes who wore all three devices concurrently. The primary outcome was the mean absolute relative difference (MARD) between CGM readings and point-of-care (POC) plasma-glucose (PG) values obtained approximately twice daily by the subjects. We compared PG values with CGM readings when available from all three CGMs in the 5 min preceding the PG values (  = 829 sets). Since the Libre Pro records readings every 15 min, we also did a two-way comparison between the G5 and the Eversense with a higher number of comparisons (  = 2277 sets). All three CGM systems produced higher average MARDs than during in-clinic studies. However, since all three CGM systems were worn by the same individuals and used the same meter for comparator PG measurements, we could directly compare their performances. In the three-way comparison, Eversense achieved the lowest nominal MARD (14.8%) followed by Dexcom G5 (16.3%) and Libre Pro (18.0%) (Eversense vs. Libre Pro  = 0.004, other comparisons  = NS). There was a statistically significant difference (  = 0.008) in the two-way comparison of the MARDs for Eversense (15.1%) and G5 (16.9%). The point accuracy of the Eversense was better than two other CGMs when compared with POC PG values.
Author Maheno, Michele M
Jafri, Rabab Z
Russell, Steven J
El-Khatib, Firas
O'Donovan, Alexander
Zheng, Hui
Hillard, Mallory A
Damiano, Edward R
Selagamsetty, Rajendranath
Balliro, Courtney A
Author_xml – sequence: 1
  givenname: Rabab Z
  surname: Jafri
  fullname: Jafri, Rabab Z
  organization: Diabetes Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA
– sequence: 2
  givenname: Courtney A
  surname: Balliro
  fullname: Balliro, Courtney A
  organization: Diabetes Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA
– sequence: 3
  givenname: Firas
  surname: El-Khatib
  fullname: El-Khatib, Firas
  organization: Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA
– sequence: 4
  givenname: Michele M
  surname: Maheno
  fullname: Maheno, Michele M
  organization: Diabetes Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA
– sequence: 5
  givenname: Mallory A
  surname: Hillard
  fullname: Hillard, Mallory A
  organization: Diabetes Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA
– sequence: 6
  givenname: Alexander
  surname: O'Donovan
  fullname: O'Donovan, Alexander
  organization: Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA
– sequence: 7
  givenname: Rajendranath
  surname: Selagamsetty
  fullname: Selagamsetty, Rajendranath
  organization: Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA
– sequence: 8
  givenname: Hui
  surname: Zheng
  fullname: Zheng, Hui
  organization: Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA
– sequence: 9
  givenname: Edward R
  surname: Damiano
  fullname: Damiano, Edward R
  organization: Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA
– sequence: 10
  givenname: Steven J
  surname: Russell
  fullname: Russell, Steven J
  organization: Diabetes Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32453604$$D View this record in MEDLINE/PubMed
BookMark eNo1kMtOwzAQRS0Eoi2wZIvmA5riOK9mWfUFUhFILWKJbGdCXTV2ZTuFfB5_hitgNZqZM1d37oCca6ORkNuYjmI6Lu8rxUeMxuWIpml5RvpxlhXROCuTHhk4t6OUFgmLL0kvYWmW5DTtk-8JbLYWMXrjHUykbC2XHUxNc-BWOaPB1OC3CDP8kqaBZTaEiRDGe1iEK-e7PcJKCYvwYs0QuK5gjdqh0Uo6mB_RulMbFLVXujWtg-W-lSaMngLjjVX6I6gflUQHSgOHB9Ng9BqAtW-r7mRg3YodSu_gU_ktbLoDQgwzxQV6dNfkouZ7hzd_9Yq8Luab6UO0el4-TierSIaffVQhpwLrOCtokgpRURbnrMqxZCGJRNCkyDiTiFmCInCiCBRP87pOq7CsGbsid7-6h1Y0WL0frGq47d7_s2Q_I9d4pQ
CitedBy_id crossref_primary_10_1109_JSEN_2024_3411570
crossref_primary_10_5772_dmht_27
crossref_primary_10_3390_s25010133
crossref_primary_10_1016_j_gerinurse_2024_06_041
crossref_primary_10_1177_19322968241310850
crossref_primary_10_1055_a_1347_2550
crossref_primary_10_3389_fchem_2022_994272
crossref_primary_10_1016_j_biosx_2024_100500
crossref_primary_10_1177_19322968231190941
crossref_primary_10_3390_s23094541
crossref_primary_10_1016_j_bios_2024_116450
crossref_primary_10_1080_17434440_2021_1982380
crossref_primary_10_1002_adsr_202400048
crossref_primary_10_3390_diabetology3020021
crossref_primary_10_3390_molecules28052353
crossref_primary_10_1111_pedi_13451
crossref_primary_10_1007_s40618_021_01624_2
crossref_primary_10_2174_0115734110290007240202154817
crossref_primary_10_2337_dc21_0629
crossref_primary_10_1111_dom_14609
crossref_primary_10_1149_1945_7111_ac6980
crossref_primary_10_3390_bios11120476
crossref_primary_10_1089_dia_2020_0672
crossref_primary_10_1002_dmrr_3537
crossref_primary_10_1007_s13410_022_01112_0
crossref_primary_10_1016_j_eprac_2021_09_010
crossref_primary_10_1016_j_eprac_2024_06_004
crossref_primary_10_1111_dom_14644
crossref_primary_10_1093_ajcn_nqac181
crossref_primary_10_3390_ijms241511980
crossref_primary_10_2337_dci23_0086
crossref_primary_10_1093_nutrit_nuae035
crossref_primary_10_1089_dia_2023_0287
crossref_primary_10_4093_dmj_2023_0083
crossref_primary_10_1089_dia_2023_0165
crossref_primary_10_2337_dci21_0035
crossref_primary_10_1364_AO_449908
crossref_primary_10_1089_dia_2021_0109
crossref_primary_10_1089_dia_2023_2502
crossref_primary_10_1016_j_cca_2020_12_025
crossref_primary_10_1021_acssensors_4c00331
crossref_primary_10_20915_2077_1177_2023_19_5_113_125
crossref_primary_10_1016_j_pcd_2022_09_005
crossref_primary_10_1111_dme_70023
crossref_primary_10_1089_dia_2024_0175
crossref_primary_10_1155_2023_1179830
crossref_primary_10_1159_000543156
crossref_primary_10_2215_CJN_0000000000000125
crossref_primary_10_1016_j_diabres_2021_109048
crossref_primary_10_1089_dia_2023_0293
crossref_primary_10_1177_1932296821997909
crossref_primary_10_1002_pdi_2482
crossref_primary_10_1007_s00125_021_05555_8
crossref_primary_10_1111_pedi_13391
crossref_primary_10_1093_ckj_sfae045
ContentType Journal Article
DBID NPM
DOI 10.1089/dia.2019.0449
DatabaseName PubMed
DatabaseTitle PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1557-8593
ExternalDocumentID 32453604
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
0R~
29F
34G
39C
4.4
53G
6PF
AAWTL
ABBKN
ABJNI
ACGFS
ADBBV
AENEX
AHMBA
ALMA_UNASSIGNED_HOLDINGS
BNQNF
CAG
COF
CS3
DU5
EBS
EJD
F5P
IAO
IER
IHR
IM4
INH
INR
ITC
MV1
NPM
NQHIM
O9-
PQQKQ
RIG
RML
UE5
ID FETCH-LOGICAL-c321t-dea0bef157034bbd02162d6e925363b0375a2cee53ebbefb734ba46ff4db03f22
IngestDate Thu Jan 02 22:58:14 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords Continuous glucose monitoring
Senseonics Eversense
Abbott Libre
Dexcom G5
Accuracy
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c321t-dea0bef157034bbd02162d6e925363b0375a2cee53ebbefb734ba46ff4db03f22
PMID 32453604
ParticipantIDs pubmed_primary_32453604
PublicationCentury 2000
PublicationDate 2020-11-00
PublicationDateYYYYMMDD 2020-11-01
PublicationDate_xml – month: 11
  year: 2020
  text: 2020-11-00
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Diabetes technology & therapeutics
PublicationTitleAlternate Diabetes Technol Ther
PublicationYear 2020
SSID ssj0007321
Score 2.4899204
Snippet There is a dearth of comparative accuracy studies of continuous glucose monitoring (CGM) devices in the home-use setting, and none with the Eversense...
SourceID pubmed
SourceType Index Database
StartPage 846
Title A Three-Way Accuracy Comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense Continuous Glucose Monitoring Devices in a Home-Use Study of Subjects with Type 1 Diabetes
URI https://www.ncbi.nlm.nih.gov/pubmed/32453604
Volume 22
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9NAEIBXKUhVL4j3G82Bm-sSr9_H0qapQOGAGtFbtevdVYOCWyWORPl3_DHEzO76QXkIuFiJ13GcnS_j2fE8GHuJalHz3ERhpeM8TBQvQ2nKKixUocYo_0QpykaevcuO58mb0_R0NPo2iFraNHKv-vLLvJL_kSruQ7lSluw_SLY7Ke7A1yhf3KKEcftXMqaAiZXW4QdxRW0fNivq3X4w7Cxo7cpD_Rm_PZimVhHY5mFosGq8H1wtdUCZC5oSBrpATlzZaqqYuw4mFLRBbykzsFnUGwqYnfood6cObPzeobYKh5wnIqDO6-F87WIU7QN81E4fbdSI9frS0jeIAh-Lsx6ax-2-oOk8_pbNQZZYH_IojMuSfy-kkP0TltdiuVy4X0MN-ZoatV6H6WQZvj3H2bNPoY4WK9GdbibOtW1DHrjoWO39xN4jgsvfqPOIaK_FU7z1pq71YqvmOR_iHA2UduGcoD_dTMYF1WLFvylFAJZ748QVVx2AdfnJkoVGaRpnro3yn0ev1fZuh7bYFq5yqG0r-Zq8HZHHPPJVYfFKXv1wHTtsu_3stfWQtYtObrNbfkED-47OO2yk67tse-ZDNu6xr_vQQQotpNBDChcGULzgIIVpugsOUegQBYsoIKK7gIBCDyh0gEIPKHhAoQcUPKCwqEFACyhYQOkCWkCBAAUCFCJoYbzP5keTk4Pj0PcNCSucsiZUWoylNhEVl0ukVGjGZlxluuQ4YbGkrs-Co3GYxlricTLHo0SSGZMoHDScP2A36otaP2LAVRWVVP-owlEhpRCyiseJMLHJizTJH7OHbvLPLl1xmLNWLE9-O_KU7fTUPmM3DWoj_RxN20a-sAR8B6IZqVg
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Three-Way+Accuracy+Comparison+of+the+Dexcom+G5%2C+Abbott+Freestyle+Libre+Pro%2C+and+Senseonics+Eversense+Continuous+Glucose+Monitoring+Devices+in+a+Home-Use+Study+of+Subjects+with+Type+1+Diabetes&rft.jtitle=Diabetes+technology+%26+therapeutics&rft.au=Jafri%2C+Rabab+Z&rft.au=Balliro%2C+Courtney+A&rft.au=El-Khatib%2C+Firas&rft.au=Maheno%2C+Michele+M&rft.date=2020-11-01&rft.eissn=1557-8593&rft.volume=22&rft.issue=11&rft.spage=846&rft_id=info:doi/10.1089%2Fdia.2019.0449&rft_id=info%3Apmid%2F32453604&rft_id=info%3Apmid%2F32453604&rft.externalDocID=32453604